Savara (SVRA) Change in Accured Expenses (2010 - 2026)
Savara (SVRA) posted quarterly Change in Accured Expenses of -$4.6 million for Q1 2026, down 47.24% year-over-year from -$8.8 million in Q1 2025, and down 227.09% quarter-over-quarter from $3.6 million in Q4 2025.
Analysis
Savara (SVRA) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Savara (SVRA) has reported Change in Accured Expenses for 17 consecutive years, with -$4.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 47.24% year-over-year to -$4.6 million; the TTM figure through Mar 2026 stood at $3.3 million (up 82.06% YoY), while the FY2025 annual figure was $4.8 million, up 14.4% from the prior year.
- Change in Accured Expenses retreated to -$4.6 million in Q1 2026 per SVRA's latest filing, from $3.6 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $3.6 million in Q4 2025 and bottomed at -$4.6 million in Q1 2026.
- Historically, Change in Accured Expenses has averaged $505529.4 across 5 years, with a median of $1.2 million in 2025.
- Annual changes were most pronounced in 2023 — Change in Accured Expenses soared 6075.0% — and 2025, when it plunged 308.83%.
- Savara's Change in Accured Expenses stood at $445000.0 in 2022, then soared by 230.34% to $1.5 million in 2023, then jumped by 53.74% to $2.3 million in 2024, then jumped by 61.37% to $3.6 million in 2025, then plunged by 227.09% to -$4.6 million in 2026.
- Business Quant data shows SVRA's Change in Accured Expenses at -$4.6 million in Q1 2026, $3.6 million in Q4 2025, and $3.1 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 11.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 55.78 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 212.44 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 61.62 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Savara | 1.36 Bn | 1.36 Bn | - | 1.48 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.48 Mn |
| Mar 31, 2026 | -4.64 Mn |
| Dec 31, 2025 | 3.65 Mn |
| Sep 30, 2025 | 3.12 Mn |
| Jun 30, 2025 | 1.19 Mn |
| Mar 31, 2025 | -3.15 Mn |
| Dec 31, 2024 | 2.26 Mn |
| Sep 30, 2024 | 1.38 Mn |
| Jun 30, 2024 | 1.34 Mn |
| Mar 31, 2024 | -770,000.00 |
| Dec 31, 2023 | 1.47 Mn |
| Sep 30, 2023 | 3.06 Mn |
| Jun 30, 2023 | 988,000.00 |
| Mar 31, 2023 | -976,000.00 |
| Dec 31, 2022 | 445,000.00 |
| Sep 30, 2022 | 1.70 Mn |
| Jun 30, 2022 | 16,000.00 |
| Mar 31, 2022 | -2.48 Mn |
| Dec 31, 2021 | -278,000.00 |
| Sep 30, 2021 | 928,000.00 |